Methodologic considerations on four cardiovascular interventions trials with contradictory results.

[1]  Samin K. Sharma,et al.  Long-Term Survival Following Multivessel Revascularization in Patients With Diabetes: The FREEDOM Follow-On Study. , 2019, Journal of the American College of Cardiology.

[2]  A. Sannino,et al.  Proportionate and Disproportionate Functional Mitral Regurgitation: A New Conceptual Framework That Reconciles the Results of the MITRA-FR and COAPT Trials. , 2019, JACC. Cardiovascular imaging.

[3]  Jeroen J. Bax,et al.  Fourth universal definition of myocardial infarction (2018). , 2018, European heart journal.

[4]  N. Freemantle,et al.  Myocardial Revascularization Trials: Beyond the Printed Word , 2018, Circulation.

[5]  M. Jeong,et al.  10-Year Outcomes of Stents Versus Coronary Artery Bypass Grafting for Left Main Coronary Artery Disease. , 2018, Journal of the American College of Cardiology.

[6]  M. Mack,et al.  Cardiovascular Outcomes Assessment of the MitraClip in Patients with Heart Failure and Secondary Mitral Regurgitation: Design and rationale of the COAPT trial , 2018, American heart journal.

[7]  Kristian Thygesen,et al.  Fourth Universal Definition of Myocardial Infarction (2018). , 2018, Journal of the American College of Cardiology.

[8]  M. Mack,et al.  Transcatheter Mitral‐Valve Repair in Patients with Heart Failure , 2018, The New England journal of medicine.

[9]  D. Maucort-Boulch,et al.  Percutaneous Repair or Medical Treatment for Secondary Mitral Regurgitation , 2018, The New England journal of medicine.

[10]  Deepak L. Bhatt,et al.  What Is the Optimal Revascularization Strategy for Left Main Coronary Stenosis? , 2017, JAMA cardiology.

[11]  Jeroen J. Bax,et al.  2017 ESC/EACTS Guidelines for the management of valvular heart disease. , 2017, European heart journal.

[12]  G. Stone,et al.  Myocardial Infarction After Percutaneous Coronary Intervention and Coronary Artery Bypass Graft Surgery: Time for a Unifying Common Definition. , 2017, JACC. Cardiovascular interventions.

[13]  L. Fleisher,et al.  2017 AHA/ACC Focused Update of the 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. , 2017, Journal of the American College of Cardiology.

[14]  P. Serruys,et al.  Quality of Life After Surgery or DES in Patients With 3-Vessel or Left Main Disease. , 2017, Journal of the American College of Cardiology.

[15]  J. Hartikainen,et al.  Percutaneous coronary angioplasty versus coronary artery bypass grafting in treatment of unprotected left main stenosis (NOBLE): a prospective, randomised, open-label, non-inferiority trial , 2016, The Lancet.

[16]  S. Pocock,et al.  Everolimus-Eluting Stents or Bypass Surgery for Left Main Coronary Artery Disease. , 2016, The New England journal of medicine.

[17]  J. Ioannidis,et al.  Head-to-head randomized trials are mostly industry sponsored and almost always favor the industry sponsor. , 2015, Journal of clinical epidemiology.

[18]  M. Mack,et al.  Coronary artery bypass grafting vs. percutaneous coronary intervention for patients with three-vessel disease: final five-year follow-up of the SYNTAX trial. , 2014, European heart journal.

[19]  M. Mack,et al.  Five-Year Outcomes in Patients With Left Main Disease Treated With Either Percutaneous Coronary Intervention or Coronary Artery Bypass Grafting in the Synergy Between Percutaneous Coronary Intervention With Taxus and Cardiac Surgery Trial , 2014, Circulation.

[20]  J. Hausleiter,et al.  Percutaneous mitral valve interventions in the real world: early and 1-year results from the ACCESS-EU, a prospective, multicenter, nonrandomized post-approval study of the MitraClip therapy in Europe. , 2013, Journal of the American College of Cardiology.

[21]  Antonio Colombo,et al.  Coronary artery bypass graft surgery versus percutaneous coronary intervention in patients with three-vessel disease and left main coronary disease: 5-year follow-up of the randomised, clinical SYNTAX trial , 2013, The Lancet.

[22]  M. Enriquez-Sarano,et al.  Independent prognostic value of functional mitral regurgitation in patients with heart failure. A quantitative analysis of 1256 patients with ischaemic and non-ischaemic dilated cardiomyopathy , 2011, Heart.

[23]  D. Taggart.  Thomas B. Ferguson Lecture. Coronary artery bypass grafting is still the best treatment for multivessel and left main disease, but patients need to know. , 2006, The Annals of thoracic surgery.

[24]  E. Romagnoli,et al.  Compliance with QUOROM and quality of reporting of overlapping meta-analyses on the role of acetylcysteine in the prevention of contrast associated nephropathy: case study , 2006, BMJ : British Medical Journal.

[25]  K. Bailey,et al.  Ischemic Mitral Regurgitation: Long-Term Outcome and Prognostic Implications With Quantitative Doppler Assessment , 2001, Circulation.